Syndax Pharmaceuticals
SNDXSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing a pipeline of first-in-class cancer therapies.
Earnings
Next report
Nov 2, 2026 (Today)Financials
Q2 2026Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing a pipeline of first-in-class cancer therapies. The company leverages strategic partnerships and in-licensing to advance treatments for high-unmet-need conditions, including acute leukemias and chronic graft-versus-host disease. Its core value proposition lies in its ability to bring novel targeted inhibitors and monoclonal antibodies from clinical development to the oncology market.
Syndax holds a first-mover advantage with the first FDA-approved menin inhibitor and maintains a strong collaborative position through a significant co-commercialization agreement with Incyte.
FAQ
- What is Syndax Pharmaceuticals's market cap?
- Syndax Pharmaceuticals (SNDX) has a market capitalization of $1.3B and trades on NASDAQ.
- What is Syndax Pharmaceuticals's revenue and profitability?
- Syndax Pharmaceuticals generated $252.3M in trailing twelve-month revenue with a net loss of $220.8M, representing a net margin of -87.5%. The latest reported period is Q2 2026.
- Who are Syndax Pharmaceuticals's competitors?
- Syndax Pharmaceuticals's key competitors include Kura Oncology, Incyte, SELLAS Life Sciences Group, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Syndax Pharmaceuticals partner with?
- Syndax Pharmaceuticals's notable partners include Incyte, Royalty Pharma, Eddingpharm, and others.
- What subsidiaries does Syndax Pharmaceuticals have?
- Syndax Pharmaceuticals's subsidiaries include Syndax Pharmaceuticals Netherlands B.V..
- Where is Syndax Pharmaceuticals headquartered?
- Syndax Pharmaceuticals is headquartered in United States of America and employs approximately 184 people. It has been publicly traded since 2016.
